Strippoli, Antonia
 Distribuzione geografica
Continente #
NA - Nord America 2.042
AS - Asia 1.530
EU - Europa 1.464
SA - Sud America 289
AF - Africa 43
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 5.372
Nazione #
US - Stati Uniti d'America 1.974
SG - Singapore 672
DE - Germania 386
CN - Cina 311
IT - Italia 288
SE - Svezia 268
BR - Brasile 225
VN - Vietnam 179
IN - India 110
FR - Francia 108
GB - Regno Unito 72
FI - Finlandia 55
IE - Irlanda 52
PL - Polonia 40
JP - Giappone 39
ID - Indonesia 38
HK - Hong Kong 35
CA - Canada 34
UA - Ucraina 34
RU - Federazione Russa 33
TR - Turchia 31
BD - Bangladesh 26
AR - Argentina 24
NL - Olanda 23
MX - Messico 21
BE - Belgio 19
IQ - Iraq 18
AT - Austria 14
EC - Ecuador 14
ES - Italia 14
IR - Iran 14
CI - Costa d'Avorio 13
ZA - Sudafrica 12
CZ - Repubblica Ceca 11
KR - Corea 10
LT - Lituania 10
SA - Arabia Saudita 9
CH - Svizzera 8
PE - Perù 7
JO - Giordania 6
PK - Pakistan 6
CO - Colombia 5
RO - Romania 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
IL - Israele 4
MA - Marocco 4
EG - Egitto 3
GE - Georgia 3
HU - Ungheria 3
PT - Portogallo 3
TN - Tunisia 3
AZ - Azerbaigian 2
BG - Bulgaria 2
BO - Bolivia 2
BY - Bielorussia 2
DK - Danimarca 2
DZ - Algeria 2
HN - Honduras 2
JM - Giamaica 2
KE - Kenya 2
LK - Sri Lanka 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PY - Paraguay 2
SN - Senegal 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
GR - Grecia 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
LB - Libano 1
LC - Santa Lucia 1
LU - Lussemburgo 1
MD - Moldavia 1
ML - Mali 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PS - Palestinian Territory 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.372
Città #
Singapore 405
Chandler 234
Ashburn 217
San Jose 164
New York 91
Beijing 63
Los Angeles 60
The Dalles 59
Chicago 56
Ho Chi Minh City 52
Hanoi 51
Dublin 49
Rome 49
Cattolica 48
Ann Arbor 46
San Mateo 39
Tokyo 38
Warsaw 37
Wilmington 37
Lauterbourg 35
Hyderabad 34
Milan 34
Jakarta 32
Council Bluffs 29
Fairfield 29
Hong Kong 29
Hefei 28
Helsinki 28
Houston 27
Munich 25
Santa Clara 25
Jacksonville 24
Nanjing 24
Boston 23
Dearborn 22
São Paulo 22
Frankfurt am Main 21
Moscow 21
Woodbridge 20
Brussels 18
Nürnberg 18
Seattle 18
Orem 17
Marseille 16
Shanghai 16
Falls Church 15
Princeton 15
Redwood City 15
St Louis 15
Boardman 14
Chennai 14
Denver 14
Abidjan 13
Dallas 13
Redmond 13
Augusta 12
Montreal 12
Manchester 11
Brooklyn 10
Brno 9
Cambridge 9
Hangzhou 9
Johannesburg 9
Kent 9
Lappeenranta 9
Lawrence 9
Nanchang 9
Toronto 9
Amsterdam 8
Da Nang 8
Guayaquil 8
Istanbul 8
Izmir 8
London 8
Mexico City 8
Nuremberg 8
Seoul 8
Turku 8
Ankara 7
Baghdad 7
Buffalo 7
Newark 7
Phoenix 7
Poplar 7
Stockholm 7
Zurich 7
Amman 6
Bari 6
Campinas 6
Curitiba 6
Düsseldorf 6
Jeddah 6
Kish 6
Mountain View 6
Mumbai 6
Paris 6
Rio de Janeiro 6
Atlanta 5
Belo Horizonte 5
Bologna 5
Totale 2.914
Nome #
C-myc expression is a possible keystone in the colorectal cancer resistance to egfr inhibitors 320
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? 307
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients 234
Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis 227
Impact of muscle mass loss on outcomes in advanced or metastatic gastric cancer patients receiving a second-line treatment 217
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. 208
Gastrointestinal stromal tumors (GISTs) and second malignancies A novel sentinel tumor? A monoinstitutional, STROBE-compliant observational analysis 182
KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study 160
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases 158
Enhanced recovery after surgery (ERAS) versus standard recovery for gastric cancer patients: The evidences and the issues: ERAS and Gastric Cancer 157
Benefit of a multimodal approach combining chemotherapy and surgery in oligometastatic gastric cancer: experience from a tertiary referral center 150
The Role of Surgery in the Management of Gastric Cancer: State of the Art 146
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 146
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas 145
Body composition changes in gastric cancer patients during preoperative flot therapy: Preliminary results of an italian cohort study 145
Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. 140
Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review. 136
Preoperative therapy and long-term survival in gastric cancer: One size does not fit all 136
The Role of Staging Laparoscopy for Gastric Cancer Patients: Current Evidence and Future Perspectives 135
First-line treatment of advanced biliary ducts carcinoma: A randomized phase II study evaluating 5-FU/LV Plus oxaliplatin (Folfox 4) versus 5-FU/LV (de gramont regimen) 134
A detailed analysis of the recurrence timing and pattern after curative surgery in patients undergoing neoadjuvant therapy or upfront surgery for gastric cancer 132
Monoinstitutional real world experience in management of vinflunine as second line therapy for transitional cell carcinoma of the urothelium 130
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. 128
Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis. 128
From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? 125
Effects of nutritional interventions on nutritional status in patients with gastric cancer: A systematic review and meta-analysis of randomized controlled trials 124
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. 123
Surgery for locally advanced gastric cancer in the era of neoadjuvant therapies: something new? 122
Real-world outcomes of Adjuvant De Gramont versus Xelox chemotherapy in reSected gasTric cancER: a propensity score-matched analysis (ASTER study) 121
Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer? 103
Gastric cancer with peritoneal metastases: a single center outline and comparison of different surgical and intraperitoneal treatments 99
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer 97
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis 96
Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis 96
Treatment of locally advanced gastric cancer (LAGC): Back to lauren’s classification in pan– cancer analysis era? 86
A detailed analysis of the recurrence timing and pattern after curative surgery in patients undergoing neoadjuvant therapy or upfront surgery for gastric cancer 84
The interference between oxaliplatin & anti-EGFR therapies: A different hypothesis to explain the 'unexplainable' 84
Totale 5.461
Categoria #
all - tutte 19.718
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.718


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202145 0 0 0 0 0 0 0 0 0 0 38 7
2021/2022437 57 18 14 71 16 15 8 55 17 27 55 84
2022/2023670 102 86 37 109 28 80 39 49 41 26 22 51
2023/2024424 18 80 12 11 10 68 38 23 21 20 33 90
2024/2025828 22 29 69 25 72 32 39 33 98 105 169 135
2025/20262.223 267 67 137 350 434 127 379 135 143 135 49 0
Totale 5.461